Generation Bio CO 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Generation Bio Co. completed its merger with XOMA Royalty Corporation, becoming a wholly-owned subsidiary and delisting from Nasdaq, while also terminating its lease and stock incentive plans.
XOMA Royalty Corporation will acquire Generation Bio Co. for $4.2913 per share in cash plus one contingent value right, with the deal expected to close in February 2026.
Generation Bio Co. announced its third quarter 2025 financial results, reporting a reduced net loss primarily due to a lease settlement gain, while actively exploring strategic alternatives.
Generation Bio Co. announced a significant leadership transition with CEO Geoff McDonough stepping down to become Board Chair, and Chief Legal Officer Yalonda Howze appointed Interim CEO and President.
Generation Bio announced new data for its ctLNP delivery system showing selective siRNA delivery to T cells in non-human primates, alongside second quarter 2025 financial results and a review of strategic alternatives.
Generation Bio Co. announced a 1-for-10 reverse stock split, effective July 21, 2025, aimed at increasing its per-share market price to regain compliance with Nasdaq's minimum bid price requirement.
Generation Bio Co. announced that its stockholders approved a reverse stock split, director elections, and other key proposals at its 2025 annual meeting, signaling potential strategic adjustments for the company's common stock.
Generation Bio reported its Q1 2025 financial results, highlighting progress in its T cell-driven autoimmune disease strategy and a cash runway into the second half of 2027.
Generation Bio reports its 2024 financial results and highlights its progress in developing siRNA therapeutics for T cell-driven autoimmune diseases using its T cell-selective lipid nanoparticle (LNP) technology.
Generation Bio Co. received a delisting notice from Nasdaq after its stock price remained below $1.00 for 30 consecutive business days.
Generation Bio is refocusing its efforts on developing siRNA therapeutics for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology, alongside executive leadership changes and a workforce reduction.
Generation Bio announced positive preclinical data demonstrating selective in vivo delivery of mRNA to T cells in non-human primates and reported its third quarter 2024 financial results.
8-K: Generation Bio Reports Second Quarter 2024 Financial Results, Cash Runway Extended Into 2H 2027
Generation Bio announced its second quarter 2024 financial results, highlighting a cash balance of $217 million expected to fund operations into the second half of 2027.
Generation Bio Co. held its 2024 annual meeting of stockholders, where key proposals including the election of directors and ratification of the company's auditor were approved.
Generation Bio announced positive data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at ASGCT, alongside its first quarter 2024 financial results.
Generation Bio reported its full year 2023 financial results, highlighting advancements in its cell-targeted lipid nanoparticle and immune-quiet DNA platforms, and a strategic focus on in vivo genetic medicine programs.
Generation Bio has terminated its lease for a 104,000 square foot manufacturing facility in Waltham, Massachusetts, citing a breach of contract by the landlord.